Value of cardiac magnetic resonance late gadolinium enhancement in predicting the risk of sudden cardiac death in hypertrophic cardiomyopathy
- VernacularTitle:心脏磁共振心肌延迟强化对肥厚型心肌病心源性猝死发生风险预测价值研究
- Author:
Li-Zhen LIU
1
;
Jia-Fei CHEN
;
Jun LUO
Author Information
- Keywords: CMR; late gadolinium enhancement; hypertrophic cardiomyopathy; sudden cardiac death; risk predictive value
- From: Journal of Regional Anatomy and Operative Surgery 2024;33(10):910-915
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the predictive value of cardiac magnetic resonance(CMR)late gadolinium enhancement(LGE)on the long-term risk of sudden cardiac death(SCD)in hypertrophic cardiomyopathy(HCM).Methods A total of 81 patients with HCM who received CMR-LGE in our hospital from October 2013 to June 2020 were selected as the study subjects,the basic data,5-year HCM-SCD risk score and LGE values of all patients,and the incidence of SCD were counted.Pearson correlation analysis was used to analyze the correlation of LGE values and 5-year HCM-SCD risk score in patients with HCM,and ROC curves was drawn to calculate the predictive efficacy of LGE values on the occurrence of SCD in patients with HCM.Results The LGE values of patients with HCM increased significantly with the 5-year HCM-SCD risk score increasing(P<0.01);Pearson correlation analysis showed that the LGE values of patients with HCM was positively correlated with 5-year HCM-SCD risk score(r=0.704,P<0.01);The ROC curve analysis revealed that the AUC of LGE values of patients with HCM predicting the risk of SCD in patients with HCM was 0.892,meanwhile,the LGE≥5.47 was the optimal threshold,with diagnostic sensitivity of 100%,and the specificity of 66.67%;The results of the Kaplan-Meier survival analysis showed that the survival rate of the LEG≥5.47 group was significantly lower than that of the LGE<5.47 group(P<0.01).Conclusion The LGE value of patients with HCM can effectively predict the risk of SCD.When the LGE value of HCM patients is≥5.47%,implantable cardioverter defibrillator should be considered for primary prevention in advance to improve the risk stratification of SCD in HCM patients.
